AR and prostate carcinoma: Cyclin K loss in prostate cancer drives androgen receptor (AR) variant expression and therapy resistance, inducing a BRCA-like deficiency (BRCAness) that increases sensitivity to PARP inhibitors, making it a key target in advanced prostate cancer [13].